BVCA Summit: LPs weigh in on GPs’ product line extensions
Investors generally welcome the expansion of product offerings, but are wary of misalignment and conflicts of interest in deal allocation.
6 October 2021•3 mins read
Investors generally welcome the expansion of product offerings, but are wary of misalignment and conflicts of interest in deal allocation.